4732

NatureWise Biotech & MedicalsTPEX:4732 Stock Report

Market Cap

NT$1.1b

7D

1.6%

1Y

-21.3%

Updated

20 Sep, 2021

Data

Company Financials
4732 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

4732 Overview

NatureWise Biotech & Medicals Corporation engages in the development of therapeutic drugs in Taiwan.

Risk Analysis

Does not have a meaningful market cap (NT$1B)


Price History & Performance

Summary of all time highs, changes and price drops for NatureWise Biotech & Medicals
Historical stock prices
Current Share PriceNT$22.15
52 Week HighNT$20.00
52 Week LowNT$30.33
Beta0.41
1 Month Change3.89%
3 Month Change-1.97%
1 Year Change-21.34%
3 Year Change17.04%
5 Year Change12.61%
Change since IPO28.51%

Recent News & Updates

Apr 29
Lacklustre Performance Is Driving NatureWise Biotech & Medicals Corporation's (GTSM:4732) Low P/E

Lacklustre Performance Is Driving NatureWise Biotech & Medicals Corporation's (GTSM:4732) Low P/E

With a price-to-earnings (or "P/E") ratio of 16.8x NatureWise Biotech & Medicals Corporation ( GTSM:4732 ) may be...

Mar 25
A Look At The Intrinsic Value Of NatureWise Biotech & Medicals Corporation (GTSM:4732)

A Look At The Intrinsic Value Of NatureWise Biotech & Medicals Corporation (GTSM:4732)

How far off is NatureWise Biotech & Medicals Corporation ( GTSM:4732 ) from its intrinsic value? Using the most recent...

Shareholder Returns

4732TW Personal ProductsTW Market
7D1.6%-1.3%-1.1%
1Y-21.3%-17.0%33.6%

Return vs Industry: 4732 underperformed the TW Personal Products industry which returned -17% over the past year.

Return vs Market: 4732 underperformed the TW Market which returned 33.6% over the past year.

Price Volatility

Is 4732's price volatile compared to industry and market?
4732 volatility
4732 Beta0.41
Industry Beta0.58
Market Beta1

Stable Share Price: 4732 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 4732's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aChung-Yang Huanghttps://www.naturewise.com.tw

NatureWise Biotech & Medicals Corporation engages in the development of therapeutic drugs in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; PPL products comprise Taiwanese Green Propolis; and NBM-BMX an oral Softgel capsule to treat cancer. The company was founded in 2000 and is based in Taipei City, Taiwan.

NatureWise Biotech & Medicals Fundamentals Summary

How do NatureWise Biotech & Medicals's earnings and revenue compare to its market cap?
4732 fundamental statistics
Market CapNT$1.09b
Earnings (TTM)-NT$268.00k
Revenue (TTM)NT$196.75m

5.5x

P/S Ratio

-4.1kx

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4732 income statement (TTM)
RevenueNT$196.75m
Cost of RevenueNT$79.46m
Gross ProfitNT$117.29m
ExpensesNT$117.56m
Earnings-NT$268.00k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0054
Gross Margin59.61%
Net Profit Margin-0.14%
Debt/Equity Ratio0%

How did 4732 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

-1,734%

Payout Ratio

Valuation

Is NatureWise Biotech & Medicals undervalued compared to its fair value and its price relative to the market?

1.87x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 4732 (NT$22.15) is trading above our estimate of fair value (NT$12.11)

Significantly Below Fair Value: 4732 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 4732 is unprofitable, so we can't compare its PE Ratio to the TW Personal Products industry average.

PE vs Market: 4732 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4732's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4732 is good value based on its PB Ratio (1.9x) compared to the TW Personal Products industry average (2x).


Future Growth

How is NatureWise Biotech & Medicals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.7%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NatureWise Biotech & Medicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has NatureWise Biotech & Medicals performed over the past 5 years?

64.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4732 is currently unprofitable.

Growing Profit Margin: 4732 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4732 is unprofitable, but has reduced losses over the past 5 years at a rate of 64% per year.

Accelerating Growth: Unable to compare 4732's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4732 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (17.9%).


Return on Equity

High ROE: 4732 has a negative Return on Equity (-0.045%), as it is currently unprofitable.


Financial Health

How is NatureWise Biotech & Medicals's financial position?


Financial Position Analysis

Short Term Liabilities: 4732's short term assets (NT$558.3M) exceed its short term liabilities (NT$44.2M).

Long Term Liabilities: 4732's short term assets (NT$558.3M) exceed its long term liabilities (NT$10.9M).


Debt to Equity History and Analysis

Debt Level: 4732 is debt free.

Reducing Debt: 4732 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 4732 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 4732 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 44.2% per year.


Dividend

What is NatureWise Biotech & Medicals's current dividend yield, its reliability and sustainability?

0.43%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 4732's dividend (0.43%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.93%).

High Dividend: 4732's dividend (0.43%) is low compared to the top 25% of dividend payers in the TW market (5.25%).


Stability and Growth of Payments

Stable Dividend: 4732 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.

Growing Dividend: 4732 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 4732 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4732's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Chung-Yang Huang

no data

Tenure

Chung-Yang Huang, Ph.D. MBA serves as Chief Executive Officer of Naturewise Biotech & Medicals Corp.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

NatureWise Biotech & Medicals Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: NatureWise Biotech & Medicals Corporation
  • Ticker: 4732
  • Exchange: TPEX
  • Founded: 2000
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: NT$1.092b
  • Shares outstanding: 49.29m
  • Website: https://www.naturewise.com.tw

Number of Employees


Location

  • NatureWise Biotech & Medicals Corporation
  • No. 36, Bade Road
  • 6th Floor
  • Taipei
  • 105
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/20 08:32
End of Day Share Price2021/09/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.